All In MedTech

FDA Clearance Tracker · P990027-S015

TECHNOLAS PERFECT VISION 217Z ZYOPTIX SYSTEM FOR PERSONALIZED VISION CORRECTION

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 30, 2010 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 30, 2010

Approved

Time to decision

154 days

Received Jun 29, 2010. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P990027-S015
Device name
TECHNOLAS PERFECT VISION 217Z ZYOPTIX SYSTEM FOR PERSONALIZED VISION CORRECTION
Applicant location
MüNchen
Received
Jun 29, 2010
Decided
Nov 30, 2010
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P990027

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code LZS

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE ADVANCED NOMOGRAM SOFTWARE MODULE AS AN UPGRADE TO THE EXISTING SOFTWARE OF THE TECHNOLAS PERFECT VISION® 217Z ZYOPTIX SYSTEM FOR PERSONALIZED VISION CORRECTION. THE ADVANCED NOMOGRAM RESIDES ON A SEPARATE COMPUTER WITH THE ZYLINK TREATMENTCALCULATION SOFTWARE, AND IT LEAVES ALL HARDWARE COMPONENTS AND THE LASER BEAM CONTROL SOFTWARE MODULE UNCHANGED. THE TECHNOLAS PERFECT VISION 217Z ZYOPTIX SYSTEM FOR PERSONALIZEDVISION CORRECTION WITH ADVANCED NOMOGRAM SOFTWARE MODULE IS INDICATED FOR WAVEFRONT-GUIDEDLASER ASSISTED IN-SITU KERATOMILEUSIS (LASIK):1) FOR THE REDUCTION OR ELIMINATION OF MYOPIA WITH SPHERE UP TO -7.00 D AND CYLINDER UP TO-3.00 D AND MRSE <=7.50 D AT THE SPECTACLE PLANE;2) IN PATIENTS WITH DOCUMENTED EVIDENCE OF A CHANGE IN MANIFEST REFRACTION OF LESS THAN OREQUAL TO +-0.50 DIOPTERS (IN BOTH CYLINDER AND SPHERE COMPONENTS) FOR AT LEAST ONE YEARPRIOR TO THE DATE OF THE PRE-OPERATIVE EXAMINATION; AND3) IN PATIENTS 21 YEARS OF AGE OR OLDER.

Source documents

Other decisions for Technolas Perfect Vision GmbH

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

4 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.